Overview

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
Phase:
Phase 2
Details
Lead Sponsor:
Hope Medicine (Nanjing) Co., Ltd